Skip to content

Episode Notes

Source / episode info

  • Episode: 353
  • Title: Divine Intervention Episode 353 – The Clutch Pulmonary HTN Podcast (for Step 1-3)
  • Published: 2021-11-24
  • Source: Episode page

One-liner

This episode provides a comprehensive review of pulmonary hypertension, covering its diverse etiologies (PAH, COPD, Scleroderma, LHF), the critical hemodynamic differentiation between proximal and distal causes, diagnostic gold standards, and the underlying molecular mechanisms of vasodilation.

High-yield summary

  • Definition: Pulmonary Hypertension (PH) is defined by a mean pulmonary arterial pressure > 25 mm Hg. The primary risk is right ventricular failure due to chronic increased afterload.
  • Hemodynamic Differentiation: PH from Pulmonary Arterial causes (proximal problem, e.g., PAH) results in high Central Venous Pressure (CVP) but normal or low Pulmonary Capillary Wedge Pressure (PCWP). Conversely, PH from Left Heart Failure/Venous causes (distal problem, e.g., Mitral Stenosis) results in elevated both CVP and PCWP.
  • Key Etiologies: Common causes include PAH (e.g., BMPR2 mutation), chronic hypoxia (COPD, IPF, OSA, Cystic Fibrosis), drug use (cocaine, methamphetamines), connective tissue disease (Scleroderma/CREST).
  • Pathophysiology of Vasodilation: PH involves decreased vasodilators like Nitric Oxide (NO) and Prostaglandins. Treatment targets include PDE5 inhibitors (e.g., Sildenafil), Endothelin Receptor Antagonists (ERA, e.g., Ambrisentan), and Prostacyclin analogs (PGI2 analogs, e.g., Iloprost).
  • Diagnosis: The screening test is an echocardiogram; the definitive diagnostic test is Right Heart Catheterization using a Swan-Ganz catheter to measure pulmonary pressures and PCWP.

Learning objectives

  • Differentiate the hemodynamic profiles (CVP vs PCWP) of pulmonary arterial hypertension versus pulmonary venous hypertension.
  • Identify common etiologies of PH based on clinical presentation (e.g., COPD for hypoxia; MS for LHF).
  • Understand the molecular targets and mechanisms of key anti-PH medications (PDE5 inhibitors, ER As, Prostaglandin analogs).
  • Interpret basic cardiac catheterization findings to distinguish between right heart failure due to PAH versus left heart failure.
  • Recognize the clinical signs and diagnostic approach for Persistent Pulmonary Hypertension of the Newborn (PPHN).

Board exam buzzwords

ConditionKey FindingAssociationBoard Exam Tip
Pulmonary Arterial HypertensionHigh PAP, Normal/Low PCWPBMPR2 mutation; Chronic HypoxiaRemember: PAH is a proximal problem. No orthopnea/PND expected.
Left Heart Failure (LHF)Elevated CVP and PCWPMitral Stenosis; Rheumatic FeverLHF causes pulmonary venous hypertension, which backs up into the capillaries, causing edema and PND.
Hypoxic PHChronic HypoxemiaCOPD, IPF, OSA, Cystic FibrosisThe body's response to low O2 is powerful vasoconstriction in the lungs.
PDE5 Inhibitors (Sildenafil)Increased cGMP levelsPhosphodiesterase type 5 inhibitionThese drugs are used to promote vasodilation by preventing the breakdown of the vasodilator signal.

Rapid review table

TopicKey PointContextExam Relevance
PH DiagnosisScreening: Echo; Diagnostic: Right Heart Catheterization (Swan-Ganz)Used to measure mean PAP and PCWP accurately.Always confirm PH diagnosis with RHC, not just echo findings.
PAH vs LHF CausePAH -> High CVP / Normal PCWP; LHF -> High CVP / High PCWPHemodynamic distinction is key to determining the source of pulmonary congestion.If PND/Orthopnea are present, suspect a venous (LHF) cause.
Hypoxia & PHHypoxic Pulmonary Vasoconstriction (HPV)COPD, IPF, Sleep ApneaChronic hypoxia drives vasoconstriction, leading to increased resistance and PAH.
Treatment TargetsNO/Prostaglandin pathways; Endothelin receptorsDrugs like Iloprost or Ambrisentan target these specific constrictive mechanisms.Knowing the mechanism helps predict drug class efficacy.

Board-speak -> diagnosis

Board-speak / Vignette phraseDiagnosis / ConceptWhy it fits
A young female patient presents with severe PAH, and genetic testing reveals a mutation in the BMPR2 gene.Pulmonary Arterial Hypertension (PAH)BMPR2 mutations are the most common cause of hereditary/idiopathic PAH.
An elderly male smoker develops chronic dyspnea and signs of right heart failure; ABG shows chronic hypoxemia.Hypoxic PH / COPDChronic lung disease leads to alveolar hypoxia, triggering hypoxic pulmonary vasoconstriction (HPV), which raises PAP.
A patient with mitral stenosis presents with progressive shortness of breath and eventually right heart failure.Pulmonary Venous Hypertension (LHF cause)Mitral Stenosis causes elevated left atrial/pulmonary venous pressure, backing up into the capillaries, causing edema and PND.
A newborn is hypoxic, but echocardiography shows a normal cardiac anatomy with persistent flow from the right to the left atrium.Persistent Pulmonary Hypertension of the Newborn (PPHN) / Persistent Fetal CirculationThis indicates failure of pulmonary vascular resistance to drop after birth, requiring specific treatment.
The patient has severe PAH and is being treated with an agent that blocks PDE5 activity.Sildenafil/PDE5 Inhibitor TherapyThese drugs increase cGMP levels by preventing its breakdown, promoting vasodilation in the pulmonary vasculature.
A patient presents with signs of right heart failure secondary to chronic sleep apnea and obesity.Obstructive Sleep Apnea (OSA) / Hypoxic PHOSA causes intermittent hypoxemia, leading to sustained hypoxic vasoconstriction and subsequent PAH/RHF.

Differential diagnosis / distinguishing features

PH from PAH vs. PH from Pulmonary Venous Hypertension

Key FeaturesDistinguishing FindingsNext Step
Problem Location: Proximal to pulmonary capillaries (arterial side).Symptoms/Signs: No orthopnea or paroxysmal nocturnal dyspnea (PND) expected because capillary hydrostatic pressure is low.Focus on therapies that reduce vascular resistance (e.g., PDE5 inhibitors).
Problem Location: Distal to pulmonary capillaries (venous side, e.g., LHF).Symptoms/Signs: High risk of fluid extravasation into the interstitium, leading to orthopnea and PND.Focus on treating the source of venous congestion (e.g., optimizing cardiac function).

Management pearls

  • Diagnosis Confirmation: While an echocardiogram is useful for screening right ventricular hypertrophy/dilation, Right Heart Catheterization remains the gold standard for confirming PH severity and measuring pulmonary pressures.
  • Hypoxia Management: In cases of hypoxic PH (e.g., COPD exacerbation), supplemental oxygen must be used cautiously; high flow O2 can sometimes worsen vasoconstriction in some settings.
  • PPHN Treatment: PPHN requires specific vasodilatory agents (like inhaled NO or systemic PDE5 inhibitors) to help the pulmonary vasculature drop its resistance, mimicking the normal postnatal transition.
  • Scleroderma Differentiation: In Scleroderma, PAH due to vascular fibrosis (CREST syndrome) is distinct from ILD-related PH; understanding this helps guide prognosis and management.

Don't miss

🚨
BMPR2 Mutation: This mutation is strongly associated with hereditary/idiopathic Pulmonary Arterial Hypertension (PAH).
🚨
LHF -> RHF Cascade: The most common cause of right heart failure is left heart failure, making the distinction between pulmonary arterial and venous causes paramount.
🚨
Obesity Hypogonadism Syndrome (OHS): This syndrome can lead to chronic hypoxemia and subsequent PAH/RHF due to combined factors like OSA and low testosterone.
🚨
CTEPH: Chronic Thromboembolic Pulmonary Hypertension results from recurrent or poorly cleared pulmonary emboli, representing a distinct cause of PH.

Integration & clinical reasoning

  • Cardiology Integration: Understanding the pressure gradients (CVP vs PCWP) is essential for interpreting cardiac catheterization data in any patient presenting with signs of heart failure or circulatory compromise.
  • Pulmonary Medicine Integration: The link between chronic lung diseases (COPD, IPF, Cystic Fibrosis) and PH via chronic hypoxia/HPV demonstrates how systemic respiratory issues can lead to severe cardiovascular complications.
  • Endocrinology Integration: While not directly discussed, the management of PAH often requires careful consideration of electrolyte balance and renal function due to associated comorbidities or medications.

Concept connections / cross-references

  • For detailed information on valvular heart disease (e.g., Mitral Stenosis), review related cardiac physiology modules.
  • For general principles of cardiac catheterization and hemodynamic monitoring, review advanced cardiology texts.
  • For understanding the pathophysiology of chronic lung diseases like COPD/IPF, refer to respiratory medicine resources.

High-yield association table

ConditionAssociationMechanismClinical Significance
PAHBMPR2 mutationGenetic defect leading to vascular remodeling and vasoconstriction.Suggests a primary vasculopathy; often requires specific PAH-targeted therapy.
COPD/IPFChronic HypoxemiaAlveolar hypoxia triggers powerful hypoxic pulmonary vasoconstriction (HPV).Leads to increased pulmonary vascular resistance, causing PH and RHF.
Mitral StenosisPulmonary Venous HypertensionIncreased pressure in the left atrium backs up into the pulmonary veins/capillaries.Causes fluid extravasation, leading to pulmonary edema, orthopnea, and PND.
Sildenafil (PDE5i)cGMP buildupInhibits phosphodiesterase type 5, preventing breakdown of the vasodilator signal.Used for PAH; promotes vasodilation by increasing cyclic GMP levels.

Key terms glossary

TermDefinitionContextExample
Pulmonary Hypertension (PH)Elevated mean pulmonary arterial pressure (>25 mm Hg).Diagnosis based on hemodynamic measurements.A patient with COPD and elevated PAP is diagnosed with PH.
PCWPPulmonary Capillary Wedge Pressure; surrogate for Left Atrial/Left Ventricular End-Diastolic Pressure.Measured via Swan-Ganz catheter.High PCWP suggests left heart failure or pulmonary venous congestion.
CVPCentral Venous Pressure; surrogate for Right Atrial Pressure.Measured via Swan-Ganz catheter.High CVP suggests right heart failure or increased systemic venous return.
PDE5 InhibitorDrug class that inhibits phosphodiesterase type 5, increasing cGMP levels.Treatment of PAH.Sildenafil is a common example used to promote vasodilation.

Study optimization

TopicStudy ApproachPriorityResources
PH Etiology & DifferentiationCreate flowcharts comparing the hemodynamic profiles (CVP/PCWP) for PAH vs LHF-related PH.High (Board-level distinction).Review board questions focusing on differentiating causes of RHF.
PharmacologyMemorize the mechanism and target receptor/enzyme for all major anti-PH drugs.Medium-High (Drug class recall).Use mnemonics: PDE5 -> cGMP; ERA -> Endothelin receptors.
Clinical PearlsPractice linking chronic lung disease, sleep apnea, and connective tissue diseases to the development of PH.High (Integration/Pattern recognition).Review cases involving COPD, IPF, and Scleroderma.

Question pattern recognition

  • Chronic Hypoxemia -> PAH: Any condition causing sustained hypoxemia (COPD, severe OSA, high altitude) should immediately raise suspicion for hypoxic pulmonary vasoconstriction leading to PH.
  • LHF/Venous Congestion -> PND/Orthopnea: If the patient has signs of fluid backup into the lungs (PND, orthopnea), suspect a problem with the left side or pulmonary veins (e.g., Mitral Stenosis).
  • PAH Diagnosis Confirmation: Always remember that while echo is screening, RHC is diagnostic. The key hemodynamic pattern is high CVP and normal/low PCWP in pure PAH.

Test yourself

Common mistakes to avoid

🚫
Mistake 1: Confusing PH causes. Assuming all right heart failure is due to primary pulmonary arterial disease. Remember, LHF/pulmonary venous hypertension can cause RHF and PND.
🚫
Mistake 2: Misinterpreting CVP/PCWP. Thinking that high CVP automatically means PAH. Always check PCWP; if both are high, suspect a left heart source (venous congestion).
🚫
Mistake 3: Overlooking the role of hypoxia. Failing to link chronic lung diseases (COPD, IPF) or sleep apnea to PH via hypoxic pulmonary vasoconstriction.

Common traps

⚠️
Trap 1: The "Left Heart Failure" trap. If a patient has LHF causing RHF, they will have PND/Orthopnea AND elevated PCWP. This is the key differentiator from pure PAH.
⚠️
Trap 2: Assuming all PH requires genetic testing. While BMPR2 is common in idiopathic PAH, other causes (COPD, Scleroderma) are far more frequent and must be considered first.
⚠️
Trap 3: Misunderstanding PDE5 inhibitors. The drug does not generate cGMP; it prevents its breakdown.

Original transcript with highlights

Original transcript with highlights

Okay, welcome. My name is Divine. This is episode 353 of the Divine Intervention Podcast. And in this podcast, I'm going to be talking about Poeminary Hepatension. If I'm going to call this the Clutch Poeminary Hepatension Podcast. One thing that you're going to find really useful with this podcast is I'm going to integrate so many things here. You're going to find this to be pretty useful. And again, if you're taking step 2, see case step 3 or complex level tour 3 within the next two months. In December or January, I would encourage you to sign up for the MD Me Testic and Strategy Score. So I have on the 6th of December from 2 to 4 30 pm, Mountain Standard Time. And then I have a 24-hour review course that's taking place from the 7th to the 10th of December. Again, we'll review a lot of medicine, surgery, IAAPIDS, OBGYN, psych, Neuro, Ethics, Biostatistics, Multisistemic Processes, and Disorders, Professionalism, Communication, Review all those things. So again, if you're interested, shoot me an email and I'll guide you in the right, I'll give you some more details on registration and reserving your spot. The course is going to be health through Zoom. And the review course is going to be from 10 pm to 4 pm, Mountain Standard Time on each of those days. Again, tons of people have taken these courses and they've done extremely well on their exams. I've had people have some very strong score increases as a result of the course. Okay, so let's just jump right into it.

What's pulmonary hypertension? Well, pulmonary hypertension basically is just pulmonary miniaturial pressure is over the magic number 25. That's pretty much it. And maybe the vine well, why is that a problem? Well, the reason is your right ventricle is normally a low pressure system. So if you start subjecting your right ventricle to crazy high pressures, it may not be able to handle that and over time it will ultimately fail. Now, what are some of the key areas our friends at the MB means love to test pulmonary hypertension? Well, they love to test it in terms of the causes, right? So I'm going to go through many of the causes and talk about the mechanisms behind that, right? So if they give you like a young female with pulmonary hypertension, right? I would really hope you're saying, oh, divine. You know, this person likely has pulmonary arterial hypertension from a BMPR2 mutation, right? Bon morphogenic protein receptor too, right? The BMPR2 mutation, when you have that mutation, you're going to have very strong fibrosis and viso-constriction of your pulmonary arteries. Remember, your right-itrum drains into your right ventricle and then your right ventricle drains into your pulmonary arteries. And then your pulmonary arteries drains into your pulmonary capillaries and then your pulmonary capillaries into your pulmonary veins. And the pulmonary veins into the left-itrum, right? And left ventricle and like that.

So if the pulmonary arteries are messed up, that's everything proximal to it is going to have increased pressures like the right ventricle, right? Or they can give you a question about a person that has really bad hypertension and they're an IV drug user or whatever. And you're asking, oh, what's causing this pulmonary hypertension? Well, I really hope you're saying, oh, divine, it can be methamphetamine is a very big cause, believe it or not. Especially people that use methamachronic bases can cause pulmonary hypertension. People that use cocaine on a chronic basis, it can cause pulmonary hypertension. Because again, those are very powerful visual active agents, right? Or they can give you a question about a person that is 60 years old and they've smoked two packs of cigarettes every day for 40 years. Well, those people likely have COPD. Well, if you have COPD, right? Again, you're going to be chronically hypoxic because remember, you need a surface area for oxygen to diffuse in the lungs, right? So if because of all those proteins, you've chewed up a lot of your lung pyrexamac. You're not going to have surface area for gas, oxygen diffusion, right? So you're going to be hypoxic. But when you're hypoxic, you begin to have hypoxic pulmonary visual constriction. And when you have that visual constriction, right, that's going to again constrict your pulmonary arteries. That's going to cause pulmonary hypertension, right?

Or they give you a question about a person that has like, you know, when they go out in the cold, like a female, she's actually going to be a female, she goes out in the cold, her hands turn like purple or white or whatever, right? And then they tell you that she has a hitch of dysphysia, right? Obviously, this is going to be scleroderma. It's going to be crescleroderma, right? People that have crescleroderma, they have like actual pulmonary arterial hypertension. There's nothing wrong with their lungs, but the actual pulmonary arteries are fibroast, so they get pulmonary hypertension from that. Now, contrast this with people that have like systemic sclerosis, right? Because remember, cresclerosis is the anti-central mirror. And then the anti-SEL70 antibodies, you know, for the systemic scleroderma, those people, they actually have like, interstitial lung disease, right? So the lungs are bad, unlike the cresclerosis people. They both have cresclerosis, they have interstitial lung disease itself. And in that interstitial lung disease, then causes them to have pulmonary arterial hypertension, right? It's a subtle difference, but it's very high you to know for, for your exams, right? So scleroderma can cause pulmonary arterial hypertension, right? Or they can give you a question about a person that has a thochmia, paroxysmone, an optional dyspnea, and all those things. And they ask you, why does this person have like right heart failure?

Again, it's going to be from the left heart, right? They have left heart failure that is causing right heart failure. Actually, this is very high you to know, the most common cause of right heart failure is left heart failure, okay? It's very high you. The most common cause of right heart failure is left heart failure, right? And a good way to differentiate right heart failure from left heart failure is that people that have left heart failure as the cause of the opponent hypertension, they will have a thochmia and paroxysmone, an optional dyspnea. But people that have pulmonary hypertension, not from left heart failure, will typically not have a thochmia or paroxysmone, an optional dyspnea, right? Again, it's very high you to understand those differences. Now, maybe bring in some more integrations as we go along, right? So again, if they give you a question about some guy, some old guy over the last six months to a year, you know, he's been having exercise intolerance, and then they tell you that again, you hear fine crackles when you listen to his lungs, right? He has IPF, he has a diopathetic pulmonary fibrosis. Again, that's going to cause chronic hypoxia, that's going to cause pulmonary viso constriction, you're going to fibrosis, your pulmonary arteries, you're going to get pulmonary hypertension, right?

Or he can give you a question about a person, he tell you that this person, you know, has not had very good childcare, and at birth, a whole lot of systolic murmur at the left-low external border was heard, right? And now this person has like signs of right heart failure. Again, the key thing to realize is that this person has eyes and fingers, right? Because they essentially had a VSD, blood kept flowing from left ventricle to right ventricle. But the right ventricle is not normally able to deal with those large amounts of blood. So over time, you have pulmonary arterial hypertension, and then what was previously left to right is anodic shunt, becomes a right to left cyanotic shunt, right? Because again, you've built up so much pressure in the pulmonary arteries, right? That's going to cause a reversal of flow from the right ventricle to the left ventricle, right? And obviously taking deoxygenated blood from the right ventricle to the left ventricle, right? That's going to cause the person to be hypoxic, right? Again, those people have eyes and fingers can certainly cause a pulmonary arterial hypertension, right? Or they give you a question about a person and they tell you that this person has pulmonary hypertension, and they have a history of like rheumatic fever, right? It's going to be again some kind of left heart failure that's causing the problem. In this case, mitro stenosis, right? So they have mitro stenosis.

Now mitro stenosis raised the person's left-eatural pressure, raised the person's pulmonary venous pressure, raised the person's pulmonary arterial pressure, and then they go to right heart failure, right? They got pulmonary hypertension. Now, if they give you a question about a person that is obese and snores, right? And then again, the person is having like, again, lower extremity, a dima, and all those signs of red heart failure. Then I really want you to think about OSA, right? Obstructive sleep apnea, or even obesity, hypogen, deletion syndrome. Again, these things can absolutely cause chronic hypoxia. And again, that chronic hypoxia, you remember your pulmonary vessels respond differently to hypoxia compared to the other vessels in the body. They respond with viso-constriction. When your viso-constrict, that's going to make it really hard for blood to drain from the right side of the heart. That's going to cause right heart failure, right? Again, that's going to cause pulmonary hypertension. Or if you even have chronic P Es, right? You see people with fat P Es, and they just seem to have never gotten better from that PE, right? You want to think about, in fact, this is something they call CTEPH, right? Chronic thrombone, volic pulmonary hypertension, right? Where they've had like P Es that the body just never really takes care of, right? So those chronic obstructions, right, again, cause pulmonary hypertension and the right heart failure, right?

So again, you know, I kind of made this big deal about orthopnea and paroxysmonectional dyspnea, telling you that, oh, you have right heart failure because of a left heart problem. Let me tell you this. You can get pulmonary hypertension from problems just with your pulmonary arteries. That's it. In that case, you will not have orthopnea or paroxysmonectional dyspnea. But if you go more distal in that pathway, you can have pulmonary hypertension from a pulmonary venous problem, pulmonary venous hypertension, right? Venous hypertension. Because if you think about it, right, right, right, atrium to right ventricle, right ventricle to pulmonary artery, pulmonary artery to pulmonary capillary, pulmonary capillary to pulmonary vein, pulmonary vein to left atrium, left atrium to left ventricle, right? So the thing is whenever you have a problem before the capillaries, before the pulmonary capillaries, right, like a problem in the pulmonary arteries, for example, then you're not going to have orthopnea or paroxysmonectional dyspnea because those are usually problems you have when your lungs are wet. People that have pulmonary arterial hypertension, the problem is prior to the pulmonary capillaries. So they are lungs because remember, capillaries tend to be more permeable, right, because they have simple, simple epithelium, right? So the thing is when people have a pulmonary arterial problem, blood is not really getting to the pulmonary capillaries that much, right?

So the hydrostatic pressures in the pulmonary capillaries are low. So they're not having a lot of fluid extraversation from the pulmonary capillaries. So they don't have orthopnea or paroxysmonectional dyspnea. However, if a person has a problem with a pulmonary vein, right, if the pulmonary hypertension is caused by pulmonary venous hypertension, right? Say for example, from a problem with the left e-trium or microstenosis or whatever, then the pulmonary vein is going to have increased pressures. And remember, your pulmonary vein is distal to your pulmonary capillaries, right? So because your pulmonary vein has increased pressures, then there's going to be a backup of fluid in the pulmonary capillaries. That's going to raise the hydrostatic pressures of those pulmonary capillaries. You're going to have fluid extraversation and you're going to get problems, right? You're going to get a thopnea and paroxysmonell paroxysmonell, nocturnal dyspnea. Again, so it's very important. Pulmonary arterial hypertension is a problem proximal to the pulmonary capillaries. So you're not going to have a thopnea or paroxysmonell nocturnal dyspnea. Now pulmonary venous hypertension is a problem that is distal to the pulmonary capillaries. So you're going to have increased hydrostatic pressures and the pulmonary capillaries, you're going to have fluid extraversation into the pulmonary pyroenchema. You're going to get a thopnea and paroxysmonell nocturnal dyspnea.

Then some other thing I guess I would mention here, whenever a person has pulmonary hyper-right heart failure because of something that's in their lungs, because of a pulmonary problem like COPD or whatever, we call it corpomunali, right? Corpomunali. But if you have right heart failure from a left heart problem, we do not call it corpomunali because the problem is from the left heart, not from the lungs. And don't forget cystic fibrosis, right? It can also be one of those things that causes pulmonary hypertension, right? Because again, those people are chronically hypoxic, they have chronic lung disease. That's going to cause hypoxic visual constriction. That's going to cause right heart failure, right? That's why cystic fibrosis again, you know, can cause just many problems along term, right? And then usually if you're listening to a person's heart that has pulmonary hypertension, you'll tell you that they have like a loud S2-heart sound, right? A loud pulmonica heart sound, right? And again, if you have pulmonary arterial hypertension many times, because your right ventricle is having to generate so much force to force blood through the pulmonary artery, you're going to get a concentric hypertrophy of the right ventricle. That's very high you to know. You're going to get a concentric hypertrophy of the right ventricle, concentric hypertrophy of the right ventricle, right? So essentially what's happening there is you're stacking your sacramirs in parallel. Right?

You're stacking your sacramirs in parallel. Right? Again, one other thing I think that may be helpful here. Again, I'm telling you the reason I'm making this podcast. Once someone requested it and two I was like, ah, there's some really high-year things that the immune system could test here. They could actually try to see if you can, if you have an understanding of the physiology in differentiating pulmonary hypertension, like pulmonary hypertension, secondary to like pulmonary arterial hypertension, versus pulmonary hypertension secondary to left heart failure. So think about it. If you have pulmonary arterial hypertension that is causing, ah, right heart failure, then your right heart pressures are going to be increased, like your CVP, your central venous pressure is going to be really, really high. But since you have pulmonary arterial hypertension, not even sending blood to the left side of the heart. So your left side heart pressures will be normal or decreased, right? So in people that have pulmonary arterial hypertension as their cause of right heart failure, their CVP is going to be up, but their PCWP, which is a surrogate for left-itre pressure will be normal or decreased because blood is literally not getting to the left side of the heart.

But if a person has left heart failure as the cause of their pulmonary hypertension, which is leading to right heart failure, since the left heart is messed up, then the left-itre pressures are going to be up, and the right-itre pressures are going to be up as well. So these people's PCWP, the pulmonary capillary wedge pressure, which is a surrogate for left-itre pressure, and the CVP, which is central venous pressure, which is a surrogate for right-itre pressure will both be increased, right? Another way they can even test pulmonary hypertension is they can give you a question about a newborn that has completely, you know, that is hypoxic, right? And you notice that, huh, this newborn is totally fine. Like you get an echocardiogram, you notice that there's nothing wrong, like the cardiachanadomy is completely normal. But you just notice that blood is still flowing from the right-itreum to the left-itre, right? Like the person seems to have like that fetal circulation that is just remaining persistent. Well, that is something that's called persistent pulmonary hypertension of the newborn, right? Persistent pulmonary hypertension of the newborn. Sometimes they call this persistent fetal circulation on MDME exams. Basically, you just notice that one. This newborn is hypoxic. So you're like, huh, is it that this newborn has like some cyanotic, congenital heart defect, like, you know, tetralogy of flow or transposition of the great vessels.

But they will tell you in the queue, that echocardiography shows normal cardiachanadomy with a persistent right to left shot. Whenever you see stuff like this, I want you to think about persistent pulmonary hypertension in the newborn. Sometimes they call this again persistent fetal circulation, right? Now, what are the key chemical agents that can appear rolling in pulmonary hypertension? Well, actually, you know, it's kind of fascinating in a science. But if you really think, if you understand this, it will make the treatments make a ton of sense to you, right? So the pathophase, right, in general, people with a half pulmonary hypertension usually have like decreased production of vasodiliders, right? Things that dilute the pulmonary arteries, right? So things like prostaglandins or nitric oxide, right? So you may say, oh, why does how does nitric oxide help with this vasodilation? Well, if you think about it, remember, nitric oxide is made many times in endothelial cells. And many times is made from the amino acid arginine, right? So arginine, right? Nitric oxide synthase will convert it to nitric oxide. And then that nitric oxide is a very powerful activator of guanilit cyclase, right? You activate guanilit cyclase, that will convert GTP, so guanosine triphosphate to cyclic GMP, right? And then that cyclic GMP activates protein kinase G, which then causes you to have smooth muscle relaxation and that will cause viso dilation.

And the thing is that cyclic GMP is actually broken down by an enzyme in the lungs known as phosphodistory is 5. PDE5 breaks down cyclic GMP and you also find PDE5 in many other tissues of the body, right? But PDE5 breaks down cyclic GMP. So, but we know that, oh, if cyclic GMP is around, you'll activate protein kinase G more, you get viso dilation. So, in general, right, phosphodistory is 5 activity. If it's working really well, it's reducing your amount of cyclic GMP and that's ultimately causing a viso constriction, right? If you understand all these things, then you'll understand how the how pulmonary hypertension is treated. And I guess another thing I should also mention is endothelene is an agent that is, I mean, look at the name endothelene. So, that means he's meeting endothelial cells, right? It's meeting endothelial cells, right? It's a very powerful viso constrictor, right? It's a very powerful viso constrictor. So, how do we treat pulmonary hypertension on NBM Es? Well, you can give a phosphodistory is 5 inhibitor, right? So, if you inhibit phosphodistory is 5, your cyclic GMP is going to build up and that's going to help, right? That because you're going to have more viso dilation, right? So, these are going to be drugs like Vardena-Fel or Seldena-Fel, right? Or you can even give something that blocks these endothelian receptors, right? So, it's going to be something like Ambricentan or Bocentan, right?

You block those endothelian receptors, you get a net viso dilation, right? And again, remember I said that decreased synthesis of things like prostaglandins and nitric oxide is what causes a person to have this net viso constriction that causes pulmonary hypertension. So, if you give a prostaglandin analog, right? So, something like ILO-prost, so that's spelled ILOPROST, right? Or Ipo-prostinol, right? Ipo-prostinol, like Ipo-PRO-ST-ENOL, right? Ipo-prostinol, that's a PGI2 analog. Do you remember PGI2? It's a Plytlet-Gatherin inhibitor, right? If something's inhibiting Plytlet-Gatherin, it'll make sense that it's also a very good viso dilator, right? So, ILO-prost, Ipo-prostinol, you can even see TREPR-ST-ENIL on your exam, T-R-E-P-R-O-F-T-I-N-I-L, TREPR-ST-ENIL, right? TREPR-ST-ENIL, TREPR-ST-ENIL, right? So, those are always your TREPR-POMENERI hypertension. If you don't see any of these drugs for some reason, you can actually give a calcium channel blocker, right? High doses of a calcium channel blocker, although it works in only about 5 or so percent of people that have pulmonary hypertension, it's like, there's this kind of pulmonary hypertension called visor reactive pulmonary hypertension. Again, there's some challenge testing you do for that, but that is well beyond the scope of our discussion right now. It's kind of the kind of thing you talk about like, I am a resident or pulmonary fellow, so we're gonna skip that for now, right?

So, I guess to wrap up today, how do we diagnose pulmonary hypertension? Well, this is easy. All you need to do is first, get an echocardiogram, right? Get an echocardiogram, right? Because the echocardiogram is sure you, if the person has like right ventricular problems or right ventricular wall thickness or things like that. But to confirm the diagnosis, right? So, the echocardiogram is like the screening test. The diagnostic test is actually a right-hot cuff, right? So, right heart catheterization, right? Basically, you pass a swan-gans catheter that will give you like very good accurate measurements of your pulmonary pressures and your PCWP and all those things, right? So, that's how you diagnose pulmonary hypertension. So, I think I'm gonna go ahead and stop here. Again, as I do at the end of every podcast, I do offer one or one tutor for all the USMEL exams. Step one, step 2 CK, step three, complex level one, two, and three, except OMM, pre-clean, comets, school exams, 30-ish-off exams. I offer again review courses for the USMEL exams, especially step 2 CK and step three and complex level two and three. Again, I have one coming up between the 6th and 10th of December. That's the one you want to attend if you're taking your test in December or January. I'm almost certain I'm not gonna be hooting a course in January. And then, I have these podcasts on Apple Podcasts, Google Podcasts, and Spotify, at least the most recent 150.

If you want everything from episode one, all the way to 353, then you need to go on the website, and then I have a You Tube channel, right? Divine Intervention, USMEL podcasts and videos. That's where I post the videos that I make. Please subscribe, again, any little bit of support certainly helps. And then, I have a new website called Divine Intervention, Life Lessons.com. So, I make podcasts like Life, podcasts that just deal with life lessons. Again, many people have found this, we really hope for. I won't have the podcast on Apple Podcasts. It's called the Divine Intervention, which is a very good idea. On Apple Podcasts, it's called the Divine Intervention, Life Lessons. So, again, if you're interested, feel free to subscribe to that. And then, I help with ERA's applications with, you know, like mock interviews, personal statements, and all those things. I do a lot of application consulting, again, I've been on an admissions committee, and I've worked with tons and tons and tons of people that are residents all over the country. In fact, some of the people I've worked with are gonna be graduating, I think, next year or something like that. Or, if even we'd be graduating this year, anyway, right? So, if you're interested in any of those things, just shoot me an email through the website. Or you can send me an email at Divine Intervention Podcasts with an SAD end at gmail.com. So, thank you for listening to me. Have a wonderful rest of your day. God bless you. Thank you.

Practice questions — USMLE style

Question 1 — Cardiology/Pulmonary Hypertension

A 55-year-old man presents with progressive dyspnea and signs of right heart failure, including peripheral edema and jugular venous distention. He has a history of chronic atrial fibrillation and poorly controlled hypertension. On physical examination, he exhibits bilateral crackles and reports waking up at night feeling short of breath (paroxysmal nocturnal dyspnea). An echocardiogram suggests elevated pulmonary pressures. Which statement best describes the underlying pathophysiology causing his right heart failure?

  • A) The primary issue is increased resistance in the pulmonary arteries due to vasculitis, leading to high central venous pressure (CVP) and normal pulmonary capillary wedge pressure (PCWP).
  • B) The chronic left atrial hypertension has backed up into the pulmonary veins, increasing hydrostatic pressure within the capillaries, which subsequently causes fluid extravasation.
  • C) The right ventricle is failing because of a primary obstruction in the main pulmonary artery, leading to decreased central venous return and low PCWP.
  • D) The elevated pressures are due to chronic hypoxemia from COPD, causing generalized hypoxic vasoconstriction that increases both CVP and PCWP equally.

Answer: B. Explanation: This patient presents with signs of right heart failure (peripheral edema, JVD) but has a history suggestive of left-sided cardiac disease (atrial fibrillation/hypertension). The transcript emphasizes that the most common cause of right heart failure is left heart failure. When pulmonary hypertension results from increased pressure distal to the pulmonary capillaries (i.e., pulmonary venous hypertension), this elevated pressure backs up into the pulmonary capillaries, raising hydrostatic pressures and causing fluid extravasation (pulmonary edema). This pattern leads to both high CVP and high PCWP (surrogate for left atrial/pulmonary venous pressure). Option A describes primary PAH (Group 1) where PCWP is normal.

Question 2 — Pulmonology/Pathophysiology

A young female patient presents with severe pulmonary hypertension. She has a known mutation in the BMPR2 gene, which results in profound fibrosis and vasoconstriction of her pulmonary arteries. Which mechanism best explains the resulting pulmonary hypertension?

  • A) Chronic hypoxemia due to impaired gas exchange, leading to generalized hypoxic pulmonary vasoconstriction.
  • B) Increased resistance proximal to the pulmonary capillaries, causing a backup of pressure into the right ventricle.
  • C) Elevated left atrial pressures transmitting retrograde backpressure through the pulmonary veins and capillaries.
  • D) Systemic inflammation causing endothelial damage that leads to decreased production of vasodilators like nitric oxide.

Answer: B. Explanation: The BMPR2 mutation is classically associated with Pulmonary Arterial Hypertension (PAH), which falls under Group 1 PH. PAH involves increased resistance proximal to the pulmonary capillaries (i.e., in the pulmonary arteries themselves). This high resistance increases pressure within the right ventricle and pulmonary artery, but because the problem originates before the capillary bed, the left heart pressures (and thus PCWP) remain normal or low.

Question 3 — Pharmacology/Pulmonary Hypertension

A patient with severe PAH is being treated with a medication that inhibits phosphodiesterase type 5 (PDE5). The mechanism of action for this drug class involves which sequence of events?

  • A) Blocking the release of endothelin, thereby preventing vasoconstriction and increasing pulmonary vascular resistance.
  • B) Increasing the synthesis of nitric oxide from L-arginine, leading to activation of guanylyl cyclase and smooth muscle relaxation.
  • C) Inhibiting PDE5 activity, allowing for the accumulation of cyclic GMP (cGMP), which activates protein kinase G and causes vasodilation.
  • D) Acting as a prostaglandin analog, thereby inhibiting platelet aggregation and directly relaxing pulmonary vascular smooth muscle.

Answer: C. Explanation: The transcript details that PAH involves decreased vasodilators like NO and prostaglandins. PDE5 inhibitors (e.g., Sildenafil/Vardenafil) work by preventing the breakdown of cyclic GMP (cGMP). By allowing cGMP to accumulate, they enhance the activation of protein kinase G, which ultimately leads to smooth muscle relaxation and vasodilation.

Question 4 — Internal Medicine/Systemic Disease

A 25-year-old woman presents with signs of pulmonary hypertension and right heart failure. She has a history of systemic sclerosis (scleroderma) confirmed by anti-Scl 70 antibodies. Physical examination reveals no evidence of interstitial lung disease, but the patient's skin shows characteristic digital pitting and Raynaud phenomenon. Which statement accurately differentiates her condition from another form of scleroderma-related pulmonary hypertension?

  • A) Her PAH is due to primary vasculitis, requiring immediate treatment with immunosuppressants targeting endothelial cells.
  • B) She has a problem originating in the pulmonary arteries (PAH), which will not cause orthopnea or paroxysmal nocturnal dyspnea.
  • C) The underlying mechanism involves interstitial lung disease causing chronic hypoxia and subsequent hypoxic vasoconstriction.
  • D) Her condition is classified as Group 2 PH because the primary pathology originates from left heart failure secondary to systemic vasculitis.

Answer: B. Explanation: The transcript highlights a critical distinction in scleroderma-related PAH. Patients with anti-Scl 70 antibodies (Systemic Sclerosis) are more likely to develop interstitial lung disease, leading to Group 3 PH (hypoxia). However, the patient described here has signs of systemic sclerosis but lacks evidence of ILD and instead presents with primary pulmonary arterial fibrosis/vasoconstriction. This means her problem is proximal to the capillaries (PAH), and therefore she will not exhibit symptoms like orthopnea or PND, which are characteristic of venous hypertension (Group 2).

Quick fire review

What is the defining pressure threshold for diagnosing Pulmonary Hypertension?

Pulmonary arterial pressure exceeding 25 mm Hg.

What is the most common cause of right heart failure?

Left heart failure (e.g., due to mitral stenosis or cardiomyopathy).

If a patient has PAH caused by left heart failure, what classic symptoms are expected?

Orthopnea and paroxysmal nocturnal dyspnea (PND), because the problem is distal to the capillaries (pulmonary venous hypertension).

What key finding differentiates primary PAH from PVH/LHF in terms of hemodynamic monitoring?

In isolated PAH, PCWP (surrogate for left atrial pressure) will be normal or decreased, while CVP (right atrial pressure) will be high.

Name two common drugs used to treat PAH that target the cGMP pathway.

PDE5 inhibitors (e.g., Sildenafil/Vardenafil).

What is the key difference in pulmonary artery pathology between CREST syndrome and systemic sclerosis?

CREST involves primary PAH due to vascular fibrosis; Systemic Sclerosis often causes PH secondary to Interstitial Lung Disease (ILD).

Which mutation is strongly associated with severe Pulmonary Arterial Hypertension (PAH)?

BMPR2 mutation.

What class of drugs are Prostaglandin analogs, and what specific $\text{PGI}_2$ analog was mentioned?

Vasodilators; Iloprost ($\text{PGI}_2$ analog).

In a patient with VSD causing pulmonary hypertension, how does the shunt flow reverse over time?

Initially Left-to-Right (L $\rightarrow$ R); high PA pressure causes reversal to Right-to-Left (R $\rightarrow$ L) cyanotic shunt.

What is the mechanism by which chronic hypoxia leads to PH in COPD patients?

Hypoxia triggers hypoxic pulmonary vasoconstriction, constricting the pulmonary arteries and raising resistance.

If a patient has PAH due to an intrinsic vascular problem (e.g., primary vasculitis), will they typically have orthopnea/PND?

No, because the problem is proximal to the pulmonary capillaries, meaning hydrostatic pressures in the capillaries are low.

What does "CTEPH" stand for and what causes it?

Chronic Thromboembolic Pulmonary Hypertension; caused by chronic thromboembolism (P Es that the body fails to clear).

Quick recall / Anki-style questions

Which mutation is strongly associated with severe Pulmonary Arterial Hypertension (PAH)?

BMPR2 mutation.

What class of drugs are Prostaglandin analogs, and what specific $\text{PGI}_2$ analog was mentioned?

Vasodilators; Iloprost ($\text{PGI}_2$ analog).

In a patient with VSD causing pulmonary hypertension, how does the shunt flow reverse over time?

Initially Left-to-Right (L $\rightarrow$ R); high PA pressure causes reversal to Right-to-Left (R $\rightarrow$ L) cyanotic shunt.

What is the mechanism by which chronic hypoxia leads to PH in COPD patients?

Hypoxia triggers hypoxic pulmonary vasoconstriction, constricting the pulmonary arteries and raising resistance.

If a patient has PAH due to an intrinsic vascular problem (e.g., primary vasculitis), will they typically have orthopnea/PND?

No, because the problem is proximal to the pulmonary capillaries, meaning hydrostatic pressures in the capillaries are low.

What does "CTEPH" stand for and what causes it?

Chronic Thromboembolic Pulmonary Hypertension; caused by chronic thromboembolism (P Es that the body fails to clear).